Parenteral formulations of rasagiline

摘要

This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release formulation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof.

主权项

1. A method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject in need of rasagiline therapy, relative to in the intestine of the subject comprising parenterally administering to the human subject a controlled released formation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof, wherein the human subject in need of rasagiline therapy is a human subject afflicted with attention deficit hyperactivity disorder (ADHD), bipolar disorder, depression, post-traumatic stress disorder (PTSD), multiple system atroply (MSA) Progressive Supranuclear Palsy (PSP), restless legs syndrome, hearing loss, glaucoma, olfactory dysfunction, Parkinson's Disease, Multiple Sclerosis (MS), Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS) or Huntington's Disease (HD).